Clinical and Translational Oncology

, Volume 12, Issue 5, pp 315–317

Treatment of localised prostate cancer with radiation therapy: evidence versus opinion

  • Ferran Guedea
  • Alfredo Ramos
  • Ismael Herruzo
  • José Antonio Sánchez Calzado
  • Jorge Contreras
  • Jesús Romero
  • Jordi Craven-Bartle
  • Patricia Willisch
  • on behalf of SEOR (Spanish Society of Radiation Oncology)
  • José Luis López Torrecilla
  • Xavier Maldonado
  • Gemma Sancho
  • Almudena Zapatero
  • on behalf of UROONCOR (Prostate Group of SEOR)
  • Montserrat Ferrer
  • Yolanda Pardo
  • Pablo Fernández
  • Alfonso Mariño
  • Asunción Hervás
  • Víctor Macías
  • Ana Boladeras
  • Ferran Ferrer
  • members of the Multicentric Spanish Group of Clinically Localized Prostate Cancer
  • Brian J. Davis
Editorial

References

  1. 1.
    Wilt TJ, MacDonald R, Rutks I et al (2008) Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 148:435–448PubMedGoogle Scholar
  2. 2.
    T. Parker-Pope, “A Review of Prostate Cancer Leaves Men in a Muddle,” New York Times, 20 February, 2008Google Scholar
  3. 3.
    Esquena S, Sánchez-Martín FM, Palou Redorta J et al (2010) Critical review of use of radiation as initial treatment for localized prostate cancer. Actas Urol Esp 34:6–9PubMedCrossRefGoogle Scholar
  4. 4.
    Thompson I, Thrasher JB, Aus G et al (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177: 2106CrossRefPubMedGoogle Scholar
  5. 5.
    Zelefsky MJ, Reuter VE, Fuks Z (2008) Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 179:1368–1373CrossRefPubMedGoogle Scholar
  6. 6.
    Stone NN, Potters L, Davis BJ et al (2009) Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7–10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 73:341–346PubMedGoogle Scholar
  7. 7.
    Roach M, Hanks G, Thames H et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65: 965–974PubMedGoogle Scholar
  8. 8.
    Zelefsky M, Yamada Y, Fuks Z et al (2008) Longterm results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71: 1028–1033PubMedGoogle Scholar
  9. 9.
    Stone N, Stock RG, Cesaretti JA, Unger P (2010) Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys 76:355–360PubMedGoogle Scholar
  10. 10.
    Zapatero A, Valcarcel F, Calvo F et al. Riskadapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR Study. J Clin Oncol 6561–6568Google Scholar
  11. 11.
    Bhojani N, Capitanio U, Suardi N et al (2010) The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys 76:342–348PubMedGoogle Scholar
  12. 12.
    Pickles T, Phillips N (2002) The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984–2000. Radiother Oncol 65:145–451CrossRefPubMedGoogle Scholar
  13. 13.
    Sanda MG, Dunn RL, Michalski J et al (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250–1261CrossRefPubMedGoogle Scholar
  14. 14.
    Ferrer M, Suarez JF, Guedea F et al (2008) Healthrelated quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 72:421–432PubMedGoogle Scholar
  15. 15.
    Korfage IJ et al (2005) Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer 116:291–296CrossRefPubMedGoogle Scholar
  16. 16.
    Chen RC, Clark JA, Talcott JA (2009) Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol 27:3916–3922CrossRefPubMedGoogle Scholar
  17. 17.
    Ficarra V, Novara G, Artibani W et al (2009) Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 55: 1037–1063CrossRefPubMedGoogle Scholar
  18. 18.
    Real Decreto 1566/1998, de 17 de julio, por el que se establecen los criterios de calidad en radioterapia. Ministerio de Sanidad y Consumo. B.O.E. núm. 206 del 28-08-1998, 29383–29394Google Scholar
  19. 19.
    Zelefsky M, Fuks Z, Hunt M et al (202) High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53:1111–1116Google Scholar
  20. 20.
    Rabbani F, Herran L, Pinochet R et al (2010) Comprehensive standarized report of complications of retropubic and laparoscopic radical prostatectomy. Eur Urol 57:371–386CrossRefPubMedGoogle Scholar
  21. 21.
    Heidenreich M, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur Eurol 53:68–80Google Scholar
  22. 22.
    National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guidelines in Oncology, available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
  23. 23.
    Donovan J, Mills N, Smith M et al (2002) Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: PROTECT (Prostate Testing for Cancer and Treatment) study. Commentary: presenting unbiased information to patients can be difficult. BMJ 325(7367):766–770CrossRefPubMedGoogle Scholar

Copyright information

© Feseo 2010

Authors and Affiliations

  • Ferran Guedea
    • 1
  • Alfredo Ramos
  • Ismael Herruzo
  • José Antonio Sánchez Calzado
  • Jorge Contreras
  • Jesús Romero
  • Jordi Craven-Bartle
  • Patricia Willisch
  • on behalf of SEOR (Spanish Society of Radiation Oncology)
  • José Luis López Torrecilla
  • Xavier Maldonado
  • Gemma Sancho
  • Almudena Zapatero
  • on behalf of UROONCOR (Prostate Group of SEOR)
  • Montserrat Ferrer
  • Yolanda Pardo
  • Pablo Fernández
  • Alfonso Mariño
  • Asunción Hervás
  • Víctor Macías
  • Ana Boladeras
  • Ferran Ferrer
  • members of the Multicentric Spanish Group of Clinically Localized Prostate Cancer
  • Brian J. Davis
  1. 1.Department of Radiation OncologyInstitut Català d’OncologiaL’Hospitalet de Llobregat, BarcelonaSpain

Personalised recommendations